Key facts
- This page summarizes Vineeta Agarwala's Form 3 filing for Braveheart Bio, Inc. (BRVE).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 14 Aug 2026, 17:00.
Vineeta Agarwala - 07 Aug 2026 Form 3 Insider Report for Braveheart Bio, Inc. (BRVE)
- Reporting relationship
- Director
- Issuer ticker
- BRVE
- Reported as of
- 07 Aug 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 14 Aug 2026, 17:00:31 UTC
- Prior SEC filing
- 28 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Vineeta Agarwala
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Vineeta Agarwala filed Form 3 for Braveheart Bio, Inc. (BRVE) on 14 Aug 2026.
Change
- Previous filing in this sequence was filed on 28 May 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002003663
Primary reporting owner
Agarwala Vineeta
- Relationship
- Director
- Address
- C/O BRAVEHEART BIO, INC., ONE LETTERMAN DRIVE, BUILDING A, SUITE A, SAN FRANCISCO
- Signature
- /s/ Vineeta Agarwala
- Signature date
- 14 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BRVE
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 10,232,420
- Date
- 07 Aug 2026
- Ownership
- By AH Bio Fund IV, L.P.
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reported securities are held by AH Bio Fund IV, L.P. ("AH Bio Fund IV"), for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P. and CLF Partners III, LP. AH Equity Partners Bio IV, L.L.C. ("AH EP Bio IV") is the general partner of AH Bio Fund IV and has sole voting and dispositive power with regard to the securities held by AH Bio Fund IV for itself and as nominee. The managing members of AH EP Bio IV are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund IV for itself and as nominee.
Footnote F2
The Reporting Person serves as one of the members of AH EP Bio IV, but she disclaims the existence of a "group" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), and disclaims beneficial ownership of the securities directly held by AH Bio Fund IV, and this report shall not be deemed an admission that she is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of her pecuniary interest therein, if any.